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Abstract
Colonic microbiota ferment non-absorbed dietary fiber to produce prodigious amounts of short chain fatty acids (SCFAs)
that benefit the host through a myriad of metabolic, trophic, and chemopreventative effects. The chemopreventative
effects of the SCFA butyrate are, in part, mediated through induction of p21 gene expression. In this study, we assessed the
role of microRNA(miRNA) in butyrate’s induction of p21 expression. The expression profiles of miRNAs in HCT-116 cells and
in human sporadic colon cancers were assessed by microarray and quantitative PCR. Regulation of p21 gene expression by
miR-106b was assessed by 39 UTR luciferase reporter assays and transfection of specific miRNA mimics. Butyrate changed
the expression of 44 miRNAs in HCT-116 cells, many of which were aberrantly expressed in colon cancer tissues. Members of
the miR-106b family were decreased in the former and increased in the latter. Butyrate-induced p21 protein expression was
dampened by treatment with a miR-106b mimic. Mutated p21 39UTR-reporter constructs expressed in HCT-116 cells
confirmed direct miR-106b targeting. Butyrate decreased HCT-116 proliferation, an effect reversed with the addition of the
miR-106b mimic. We conclude that microbe-derived SCFAs regulate host gene expression involved in intestinal homeostasis
as well as carcinogenesis through modulation of miRNAs.
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Introduction
Most human sporadic colon cancers develop gradually as accu-
mulating alterations in gene expression transform normal colonic
epithelium to adenocarcinoma. This process involves an interplay
between genetic and environmental factors, the latter supported by
the epidemiological association between increased incidence of
colorectal cancers and factors such as increased longevity,
exposure to carcinogens, and diets in highly industrialized
countries [1]. Among the proposed dietary risk factors is low fiber
content, which may lower the bioavailability of short chain fatty
acids (SCFAs) that are formed by microbial anaerobic fermenta-
tion of dietary fiber [2]. SCFAs such as acetate, proprionate, and
butyrate are produced in prodigious amounts and are the most
abundant anions in colonic luminal fluid and feces [3]. These
microbial products not only provide an important source of energy
to the colonic epithelium, but also have widespread trophic effects
that include regulation of host genes involved in maintenance of
intestinal homeostasis [4].
In undifferentiated, highly proliferative malignant cells, butyrate
inhibits proliferation and induces differentiation through a variety
of mechanisms including alterations in DNA methylation, selective
inhibition of histone phosphorylation and histone deacetylation
(HDAC), and modulation of intracellular kinase signaling [5–7]. In
a human colonic epithelial cell line (HT29), 221 butyrate
responsive genes involved in proliferation, differentiation, and
apoptosis were identified [6]. Amongst the genes altered by
butyrate treatment were many involved in cell cycle regulation,
such as the cyclin dependent kinase inhibitor p21, GADD45A,
and PTEN [6].
Under normal conditions, proliferation is tightly regulated
through the action of cyclins, cyclin dependent kinases (CDKs),
and CDK inhibitors which regulate the transitions from G1 to S
phase and G2 to mitosis and act as checkpoints to prevent
replication if DNA is damaged [8]. In response to signals
indicating DNA damage, p21 and p27 bind to cyclin-CDK
complexes and induce cell cycle arrest [8,9]. However, in cancer,
this regulated process of cell division and growth is lost. For
instance, loss of function of the G1 checkpoint cyclin dependent
kinase inhibitor p21 has been linked to carcinogenesis and p21 loss
is observed in 79% of colon cancer tumors by immunohistochem-
istry [10,11].
Butyrate induces p21 gene transcription via a p53 independent
pathway involving non-competitive inhibition of HDAC [12–14].
However, the possibility that some of butyrate’s actions on p21
gene expression might be mediated through miRNA-dependent
translational mechanisms has not been previously explored.
HDAC inhibitors have recently been studied as a new group of
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suberoylanilide hydroxamic acid (SAHA), is FDA approved for the
treatment of cutaneous T cell lymphoma [15]. Furthermore,
HDAC inhibitors have been implicated in miRNA regulation in
multiple types of malignancies. Treatment of the breast cancer cell
line SKBr3 with the hydroxamic acid HDAC inhibitor LAQ824
led to significant changes in ,40% of the cell’s expressed miRNAs
[16]. SAHA treatment of the human lung carcinoma cell line
A549 led to significant alterations in the expression of 64 miRNAs
[17]. The influence of the HDAC inhibitor and microbial product
butyrate on miRNA expression in colon cancer tissues has not
been investigated.
miRNAs are ,22 nucleotide, non-coding RNAs that play an
important role in regulating cell proliferation, apoptosis, and
differentiation [18]. Greater than 1000 human miRNAs have been
identified, and most are believed to target hundreds of genes [19].
Dysregulation of miRNA expression can contribute to carcino-
genesis by increasing proto-oncogene expression or down-
regulating tumor suppressors [20]. For example, miRNAs regulate
many key proteins in the signaling pathways of colorectal cancer,
e.g. the miR-106b family reduces p21 expression and affects cell
cycle progression [21–23]. Amongst the miR-106b predicted
targets, silencing of p21 with siRNA most closely phenocopies
miR-106b gain of function [22].
In this study, we hypothesized that the anti-cancer effects of the
microbe derived SCFA butyrate may be mediated in part via
changes in miRNA expression. We performed miRNA microarray
studies on human colon cancer HCT-116 cells treated with
butyrate and found significant alterations in miRNA profiles,
including decreased expression of the miR-106b family. miRNA
microarray analysis of sporadic-type human colon cancers found
increased expression of the miR-106b family. Butyrate was found
to induce p21 expression, which was associated with a significant
decrease in cell proliferation. The addition of a miR-106b mimic
reversed the increased p21 expression and decreased cell
proliferation induced by butyrate. These findings have uncovered
a unique mechanism of microbial interaction with host gene
expression that involves alterations of miRNA profiles to restrain
cell cycling and inhibit colon cancer cell proliferation.
Materials and Methods
Ethics Statement
Surgical human colonic biopsies were obtained from colon
cancer patients at the University of Chicago Medical Center under
a protocol approved by the Institutional Review Board. Written
informed consent was obtained prior to the collection of tissue
specimens. All clinical investigations using human subjects were
conducted according to the principles expressed in the Declaration
of Helsinki.
Cell Culture
Human HCT-116 colon cancer cells were acquired from ATCC.
Cells were grown at 37uC in high glucose DMEM medium
(Invitrogen) containing 10% (vol/vol) fetal bovine serum, 50 mg/ml
L-glutamate, 50 mg/ml streptomycin, and 50 U/ml penicillin. Cells
were treated with 1–2 mM butyrate for 24 to 48 hours prior to
harvest for each individual assay. Cells were rinsed twice and
scraped into ice-cold phosphate buffered saline (PBS), pelleted
(14,000 g620 sec), then lysed for RNA and protein extraction.
Human colonic biopsies
Surgical human colonic biopsies from tumor tissue and
surrounding normal appearing colonic mucosa (at least 5 cm
away the tumor border) were obtained by a colorectal surgeon.
After removal, biopsies were immediately placed on ice and rinsed
in ice-cold PBS prior to cell lysis for RNA extraction.
miRNA microarray
Total RNA was extracted from HCT-116 cells and human
colonic tissue samples using the mirVana
TM miRNA Isolation Kit
(Ambion) according to the manufacturer’s protocol. HCT-116 cell
miRNA was analyzed using the miRCURY LNA
TM microarray
v.11.0 (Exiqon) that contains capture probes targeting all miRNAs
for human, mouse, or rat registered in the miRBase version 13 at
the Sanger Institute. All samples were pooled to create a common
reference. One mg total RNA from each sample and the pooled
common reference was labeled using the miRCURY
TM LNA
Array power labeling kit (Exiqon, Denmark). The Hy3
TM-labeled
samples and a Hy5
TM-labeled reference RNA sample were mixed
pair-wise and hybridized to the miRCURY
TM LNA arrays. The
microarray slides were scanned using the Agilent G2565BA
Microarray Scanner System (Agilent Technologies, Inc., USA)
and the image analysis was carried out using the ImaGene 8.0
software (BioDiscovery, Inc., USA). The quantified signals were
background corrected (Normexp with offset value 10) and
normalized using the global Lowess (LOcally WEighted Scatter-
plot Smoothing) regression algorithm [24]. The data is expressed
as the normalized log2 transformed Hy3/Hy5 ratio.
In a similar fashion, human colonic tissue miRNAs were
analyzed using mirVana miRNA Bioarrays v.2 (Ambion), which
utilizes version 8.0 of the miRBase sequence database. The
samples were labeled with the mirVana miRNA labeling kit and
hybridized to the miRNA bioarrays per the manufacturer’s
instructions. The arrays were scanned using the GenePix4000B
in the University of Chicago Functional Genomics Core Facility.
A total of 12 miRNA profiles were generated from 6 paired
colonic tissue samples.
Real-time PCR for miRNAs
Total RNA was extracted from pelleted HCT-116 cells by
Trizol (Invitrogen, Grand Island, NY) according to the manufac-
turer’s instructions. Complementary DNA was synthesized from
total RNA samples extracted from HCT-116 cells or human colon
tissues using the NCode
TM miRNA First-Strand cDNA Synthesis
Kit (Invitrogen). Real-time PCR was performed with an iCycler
(Bio-Rad) using the iQSYBR Green PCR supermix (Bio-Rad) with
miRNA specific primers and a universal qPCR primer according
to the manufacturer’s protocol for the NCode Kit (Table S1). The
two-step quantification cycling protocol (45 cycles of 95uC for 15
seconds and then 60uC for 15 seconds) was used. The Ct value is
defined as the cycle number at which the fluorescence crosses a
fixed threshold above the baseline. A small nucleolar RNA,
RNU48, was measured as endogenous control [25]. For a relative
quantification, fold changes were measured using the DDCt
method. For each sample, the Ct value of each miRNA was
measured and compared to RNU48 as DCt, (DCt = Ct miRNA –
Ct RNU48). The fold change of miRNA in experimental samples
relative to control samples was determined by 2
2DDCT, where
DDCt = DCt Unknown –DCt Control [26].
Real-time PCR for p21 mRNA
Total RNA was extracted from pelleted HCT-116 cells with
Trizol. Complementary DNA was synthesized using SuperScript
III (Invitrogen) and a random hexonucleotide primer. The sense
and antisense primers for p21 (CDKN1A, NM_000389.3) are: 59-
TCACTGTCTTGTACCCTTGTGCTT-39 and 59- AGAAAT-
CTGTCATGCTGGTCTGCC-39; for GAPDH: 59-GGCAAA-
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CCC-39. Real-time PCR was performed with an iCycler using
iQSYBR Green PCR supermix (Bio-Rad). For each sample, the
Ct value of p21 mRNA was measured and compared to the
GAPDH endogenous control as DCt, (DCt = Ctp21 –C tGAPDH).
The fold change of miRNA in experimental samples relative to
control samples was determined by 2
2DDCT.
Western Blot
Pelleted HCT-116 cells were homogenized in 10 mM Tris,
pH 7.4, 5 mM MgCl2, complete protease inhibitor cocktail
(Roche Molecular Biochemicals), 50 U/ml DNAse (Amersham),
and 50 U/ml RNAse (Ambion). Protein was quantified using the
bicinchoninic acid method. Protein was solubolized in 3X
Laemmli stop solution by heating to 65uC for 10 minutes.
Twenty microgram protein samples were separated by SDS-
PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes in 25 mM Tris, pH 8.8; 192 mM glycine; 15% vol/
vol methanol. Membranes were blocked with 5% wt/vol non-fat
dry milk in tween-tris buffered saline (TTBS). Primary antibodies,
specific for p21 (BD Bioscience), Hsc70 (SPA815; Stressgen) and b-
actin (Cell Signaling), were added and incubated overnight at 4uC.
Membranes were washed with TTBS, incubated with horseradish
peroxidase-conjugated species-appropriate secondary antibodies
(Jackson Immunoresearch, West Grove, PA) for 1 hour at room
temperature, and developed using an enhanced chemiluminescence
system (Supersignal; Pierce, Rockford, IL).
Quantification of images was done by scanning densitometry
using NIH Image J 1.54 software (National Institutes of Health,
Bethesda, Maryland).
Cell Proliferation Assay
Cell proliferation was measured using the WST-1 reagent (Roche
Applied Science) according to the manufacturer’s protocol. HCT-
116cellswereculturedona 96wellflat-bottomplate.Afterreaching
50%confluence,wellsweretreatedwiththeindicatedconcentration
of butyrate for 24 hrs. Plates were read on a microplate reader at
450 nm before and 45 minutes after adding the WST-1 reagent.
The referencewavelength was650 nm.Cellproliferationrates were
calculated according to the manufacturer’s protocol.
Cell transfection with miRNA
TransIT-LT1 (Mirus, WI) transfection reagent was used to
transfect HCT-116 cells with an engineered miR-106b (Ambion’s
Pre-mir MiRNA Precursor Molecules) according to the manufac-
turer’s protocol. A control miRNA (miR-C), with identical GC
content but no sequence homology to miR-106b, was used as a
control. Cells were transfected for 48 hours prior to harvest.
Luciferase Reporter Assays
Modified pGL3 constructs with the p21 39UTR downstream of
the firefly luciferase coding sequence were a generous gift from Dr.
V. Narry Kim of the Department of Biological Sciences, Seoul
National University [27]. Six hours after butyrate treatment,
HCT-116 cells were transiently transfected with modified pGL3
constructs and pRL-TK plasmids (Renilla luciferase driven by
thymidine kinase promoter, E2241, Promega) using the TransIT
LT-1 transfection reagent. Cells were harvested by shaking in
500 ml lysis buffer (Promega). Firefly and Renilla luciferase activities
in the lysate were determined in triplicate with a Dual-Luciferase
Reporter assay system, according to the manufacturer’s instruc-
tions (Promega). Firefly luciferase activity was normalized to Renilla
luciferase activity.
Statistical Analysis
Results are presented as mean 6SEM for the indicated number
of experiments. The results of multiple experiments were analyzed
by student’s t-test or ANOVA using Bonferroni correction for
multiple comparisons.
For the miRNA arrays, a two-tailed T-test calculated between
the sample and reference groups identified miRNAs with p-values
lower than 0.05. These miRNAs were then chosen for further
study with RT-PCR.
Results
Butyrate alters miRNA expression in human colon cancer
HCT-116 cells, including members of the miR-106b family
To study the effects of butyrate on miRNA expression in colonic
cancer cells, expression profiles of miRNAs in butyrate-treated
HCT-116 cells were measured using a microarray. Vehicle-treated
HCT-116 cells were analyzed as a control. Forty-four miRNAs
demonstrated significant changes in expression in response to
butyrate treatment. The changes in expression of 13 of the 26
miRNAs that decreased and 5 out of the 18 miRNAs that increased
were confirmed using real-time, quantitative PCR (Figure S1).
Thirty-one of the 44 miRNAs with changes in expression are shown
in the heat map on the left panel of Figure 1A. Multiple members
of the miR-17-92a, miR-18b-106a, and miR-25-106b clusters were
significantly decreased in response to butyrate.
Expression levels of these miRNAs were also assessed in human
sporadic colon cancers and surrounding normal appearing colon by
microarray and are shown in the right panel of Figure 1A. The
miRNAs decreased in butyrate-treated HCT-116 cells were
dramatically increased in tumor tissues as compared to normal
controls. miRs-17, -20a, -20b, -93, -106a and -106b were all
decreased in response to butyrate treatment. These miRNAs share
the same seed region sequence and thus target the same binding
sites in the 39UTRs of target mRNAs. Using real time PCR, we
confirmed that butyrate down-regulated these miRNAs in HCT-
116 cells (Figure 1B). We also confirmed that these miRNAs were
highly over-expressed in human colon cancer samples (Figure 1C),
suggesting that some anti-cancer effects of butyrate are mediated by
suppressing the miRNAs that are upregulated in colon cancer.
miR-106b inhibits butyrate-induced p21 protein
expression
Prior studies showed that the 39UTR of p21, which regulates cancer
cell proliferation, contains two binding sites for the miR-17 – 106b seed
sequence (Figure 2A) and is inhibited by these miRNAs in various
types of cancer [reviewed in 13–15, 22]. We, therefore, analyzed the
effects of butyrate and a miR-106b mimic on p21 mRNA and protein
levels in HCT-116 cells. As shown in Figure 2B and 2C, butyrate
increased p21 protein expression four fold after 24 hours of treatment.
An exogenous miR-106b mimic dampened butyrate-induced p21
protein expression as compared with cells treated with butyrate alone
whereas control miRNA molecules had no effect on p21 expression.
To determine the effect of butyrate and miRNAs on p21 gene
expression, cellular p21 mRNA levels were measured by real-time
PCR (Figure 2D). Butyrate induced a 3.6-fold increase in p21
mRNA abundancy. In contrast, the miR-106b mimic had no
effect on p21 mRNA expression.
The 39UTR of p21 mediates translational regulation by
butyrate and miR-106b
To investigate the effect of miR-106b on translational regulation of
p21 expression, HCT-116 cells were transiently transfected with
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p21 39UTR or p21 39UTRs containing mutations in either one or
both of the miR-106b binding sites (Figure 3A). Firefly luciferase
expression was used to assess cis regulation via the p21 39 UTR. The
pRL-TK vector expressing Renilla luciferase was co-transfected to
control for transfection efficiency. Under basal conditions, mutations
in the individual miR-106b target regions in the p21 39UTR at
nucleotides 468-474 and nucleotides 1148-1154 resulted in a 28%
and 26% increase in luciferase activity respectively (Figure 3B).
Furthermore, mutations in both miR-106b target regions resulted in
a 57% increase in luciferase activity, suggesting that both binding sites
mediate miRNA inhibition of basal p21 expression in cancer cells.
Butyrate stimulated luciferase activity 85% over control in
HCT-116 cells transfected with the luciferase containing p21 39
UTR vector (Figure 3C). Butyrate’s effects on luciferase
expression were reversed by the addition of exogenous miR-
106b mimics, but not control miRNA molecules (miR-C).
Furthermore, the luciferase activity of HCT-116 cells transfected
with the chimeric vector containing both mutant miR-106b target
sites was not altered with butyrate treatment or with butyrate in
the presence of exogenous miR-106b.
Butyrate’s effect on cell proliferation is inhibited by miR-
106b
Since p21 inhibits cell cycle progression, we examined the role of
miR-106b on butyrate’s anti-proliferative effects. HCT-116 cells
were treated with multiple dilutions of butyrate for 24 hours and a
WST-1 proliferation assay was performed. As shown in Figure 4A,
butyrate dose-dependently inhibited cell proliferation. The anti-
proliferative butyrate concentrations wereinthe physiological range
of 0.5 to 20 mM [28,29]. Cells transfected with exogenous miR-
106b or control for 24 hrs prior to 2 mM butyrate exposure were
also analyzed (Figure 4B). The butyrate-induced inhibition of cell
proliferation was reversed by the addition of miR-106b mimic
molecules in a dose-dependant manner (Figure 4B). In contrast,
control miRNA molecules (miR-C) showed no effect on the
butyrate-induced inhibition of cell proliferation.
Discussion
In this study, we identify, for the first time, an important growth
regulatory role for colonic epithelial miRNAs in mediating the
effects of the microbe-derived short chain fatty acid butyrate on
Figure 1. Butyrate treatment of HCT116 cells alters expression of miRNAs aberrantly expressed in human colon cancers. A) miRNA
microarray profiles were performed on RNA extracted from HCT-116 cells treated with vehicle or 1 mM butyrate and human colon tissues from
patients with sporadic colonic cancer and adjacent normal-appearing tissue. Data was normalized using the global Lowess regression algorithm and
is expressed as log base 2 transformed ratios of the sample signal to the control reference pool signal. Heat maps are represented. The red color in
the heat map represents increased expression as compared to the pooled reference control, and green represents decreased expression as compared
to the pooled control. Changes in expression of the miR-17 – 106b family were confirmed by real-time PCR in B) HCT-116 cells and C) human colon
tissues. Results are means 6 SE, n=4. * indicates p,0.05 for sample as compared to control.
doi:10.1371/journal.pone.0016221.g001
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suppressed many of the same miRNAs increased in human colon
cancers. One of these miRNAs, miR-106b, was found to target
p21. Butyrate and miR-106b treatment of a p21 39UTR luciferase
reporter construct in HCT116 cells indicates that butyrate-
stimulated p21 expression is translationally inhibited in part by
miR-106b. This partial inhibition by miR-106b confirms previous
reports that butyrate also regulates p21 expression via a miRNA
independent mechanism, through its inhibition of HDAC
[7,13,14]. We propose that the microbial product butyrate
regulates the cell cycle through both epigenetic and translational
regulation through its dual role as a HDAC inhibitor and inhibitor
of miR-106b expression (Figure 5).
These results have important implications for intestinal
homeostasis and carcinogenesis. These data would suggest that
these miRNAs play a role in colonic carcinogenesis and that their
reduction by butyrate is an important mechanism of its anti-cancer
effects. Six of these miRNAs are in the same miRNA family (miR-
17, miR-20a, miR-20b, miR-93, miR-106a, and miR-106b), share
an identical seed sequence, and thus target the same binding sites
in the 39UTRs of target mRNAs. Therefore, suppression of their
target genes during the carcinogenic process might represent a
patterned cell response to promote cell proliferation and/or
maintenance of the undifferentiated state.
Because many miRNAs are also located in intronic regions of
encoding genes, the miRNA response is likely coordinated with
transciptionally activated genes that contribute to the overall
process of carcinogenesis. As an example pertinent to our findings,
the miR-106b-25 polycistron is located within intron 13 of the
MCM7 gene on chromosome 7q22.1 [23]. MCM7 (minichromo-
some maintenance protein 7) regulates DNA replication during
the S phase. In quiescent cells, human MCM7 mRNA levels are
almost undetectable, but its expression is induced as cells enter the
cell cycle. The MCM7 promoter has three E2F sites, three GC
Figure 2. Butyrate-induced p21 protein expression is inhibited by miR-106b. A) Schematic of common seed regions in the miR-17 – 106b
family that target the p21 39UTR at two sites. HCT-116 cells were treated with butyrate (2 mM) or vehicle and were transfected with miR-106b mimic
or control miRNA (miR-C) for 24 hours prior to harvest. B) Western blots for p21, b-actin and Hsc70 are shown, and are representative of 4 individual
experiments all with similar results. C) Densitometry results of Western blots of p21 normalized to b-actin. D) p21 mRNA abundance was analyzed by
real-time PCR. Results are means 6 SE, n=4. * indicates p,0.05 compared to basal. # indicates p,0.05 compared to control.
doi:10.1371/journal.pone.0016221.g002
Butyrate Regulates p21 through miRNAs
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16221boxes, and an E box [30]. In hepatocellular carcinoma (HCC), the
expression of the miR-106b precursor strongly correlates with
MCM7 expression, indicating that the miR-106b-25 polycistron is
coordinately transcribed under the influence of the MCM7
promoter. High levels of expression of the transcription factor
E2F1 in HCC also correlated with increased miR-106b expression
[31]. In gastric cancer cells, E2F1 also appears to regulate miR-
106b-25 expression in parallel with increases in MCM7 expression
[32]. In mouse fibroblasts transformed with the EIA and Ras
oncogenes, butyrate decreases E2F1 transcripts and protein as well
as promoter activation [33]. Thus, butyrate might exert its effect
on miR-106b expression via decreased E2F1 expression, though
further studies in HCT-116 cells are needed to examine this
possibility.
As stated previously, dysregulation of miRNA expression can
influence carcinogenesis when the miRNA targets are tumor
suppressors or oncogenes. While treatment with miR-106b leads
to decreased p21 protein expression, p21 mRNA levels do not
change, which is consistent with prior reports that miR-106b
regulates p21 through translational inhibition rather than mRNA
stability [32]. Although miR-106b regulation of p21 expression has
been described in many cell types, there is conflicting data on the
mechanism of this interaction. In human mammary epithelial cells
and normal lung fibroblasts, miR-106b decreased the p21 mRNA
by about 40% [22]. In contrast, in HCC, p21 expression showed
no correlation with the expression of the miR106b-25 cluster, and
did not seem to be a target of these miRNAs in this cell type [31].
In a human gastric carcinoma derived cell line, miR-106b
repressed p21 protein expression, but did not cause a significant
change in p21 mRNA levels [32].
In summary, we have discovered a novel mechanism of action
for butyrate’s anti-cancer effects involving modulation of miRNA
Figure 3. miR-106b regulates p21 translation via two target
sites in the 39UTR. A) Schematic of the luciferase reporter constructs
containing the p21 mRNA 39UTR, which includes two binding sites for
the miR-17-106b family. Mutations were generated in these miR-106b
target sites. HCT-116 cells were transiently co-transfected with firefly
luciferase pGL3 vectors containing the wild type or mutated p21 39UTR
and pRL-TK Renilla luciferase control vector. Cells were also treated with
butyrate (2 mM) or vehicle and miR-106b mimic or control miRNA
molecules (miR-C). Cells were harvested for luminescence measurement
48 hrs after transfection. B) Basal luciferase expression of reporter
constructs with wild type or mutated p21 39UTR. * indicates p,0.05
compared to p21 39UTR C) Luciferase expression in cells after butyrate
and miRNA treatment. * indicates p,0.05 compared to control. Results
are means 6 SE, n=4.
doi:10.1371/journal.pone.0016221.g003
Figure 4. miR-106b reverses butyrate’s anti-proliferative
effects. HCT-116 cell proliferation rate was measured with the WST-1
proliferation kit. A) HCT-116 cells were treated with the indicated
concentration of butyrate or vehicle for 24 hrs before WST-1
measurement. * indicates p,0.05, compared to basal B) HCT-116 cells
were transfected with the miR-106b mimic or control miRNA (miR-C)
with the indicated concentrations immediately before treatment with
2 mM butyrate. Cells treated only with butyrate were analyzed as
Control. * indicates p,0.05 compared to butyrate alone. Results are
means 6 SE, n=5.
doi:10.1371/journal.pone.0016221.g004
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example, butyrate induces expression of p21, a key regulatory
molecule of cell cycle arrest, by suppressing members of the miR-
106b family. Butyrate inhibition of miR-106b is also associated
with a significant decrease in cancer cell proliferation rates. The
latter is reversed by the addition of miR-106b mimics. These
findings have uncovered a unique example of microbial regulation
of host gene expression that retards cell cycling and inhibits colon
cancer cell proliferation.
Supporting Information
Figure S1 Butyrate significantly alters the expression of
forty-four miRNAs in HCT-116 cells. HCT-116 cells were
treated with 1 mM butyrate for 24 hrs. Isolated total RNA
was subjected to miRNA array hybridization. Forty-four miRNAs
demonstrated significant changes in expression in response to
butyrate treatment. Microarray data was normalized using the
global Lowess regression algorithm and is expressed as log base 2
transformed ratios of the sample signal to the control reference
pool signal. The changes in miRNA expression were confirmed
using real-time, quantitative PCR for 13 of the 26 miRNAs that
decreased and 5 of the 18 miRNA s that increased.
(TIF)
Table S1 Primers Used for Quantitative Real-Time
Polymerase Chain Reactions. Complementary DNA was
synthesized from total RNA samples extracted from HCT-116
cells or human colon tissues using the NCode
TM miRNA First-
Strand cDNA Synthesis Kit (Invitrogen). Real-time PCR was
performed with an iCycler (Bio-Rad) using the iQSYBR Green
PCR supermix (Bio-Rad) with miRNA specific primers consisting
of the entire sequence of the miRNA of interest and a universal
qPCR primer according to the manufacturer’s protocol for the
NCode Kit.
(DOC)
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